Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• FedEx Freight forecasts growth after spin-off despite margin pressure in Q4
• JPMorgan Upgrades PT Perusahaan Gas Negara Tbk (PGAS:JK) (PPAAF) to Overweight